BillionToOne: 3 Key Takeaways for Long-Term Investors
Gross margin held at 71% while cost per test stayed near $169, a sign that growth is not being bought with debt.
Three key insights emerge from BillionToOne's (BLLN) earnings call on November 4, 2026. Firstly, the company raised its 2026 revenue guidance to between $460 million and $470 million, reflecting 47% year-over-year revenue growth to $123 million. This represents five consecutive quarters of positive GAAP operating income. Secondly, BillionToOne plans to launch Northstar Clear, a tissue-free minimal residual disease (MRD) test, on December 15, 2026.
This test offers several advantages over traditional tissue-dependent assays, including faster results and lower failure rates. Lastly, the company's gross margin reached 71% in the third quarter, driven by cost savings from software automation and high test throughput. These factors have enabled BillionToOne to achieve GAAP profitability and cash flow positivity, with a fraction of the accumulated deficit compared to its public peers.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
